• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Undertreatment and Underachievement of LDL-C Target among Individuals with High and Very High Cardiovascular Risk in the Malaysian Community.马来西亚社区中具有高和极高心血管疾病风险的个体低密度脂蛋白胆固醇(LDL-C)目标的治疗不足与未达目标情况。
Healthcare (Basel). 2022 Dec 5;10(12):2448. doi: 10.3390/healthcare10122448.
2
The effect of the intensity of lipid-lowering medications on the LDL cholesterol treatment goals of Asian patients with dyslipidaemia in primary care.降脂药物强度对基层医疗中血脂异常亚洲患者低密度脂蛋白胆固醇治疗目标的影响。
J Clin Pharm Ther. 2016 Dec;41(6):677-683. doi: 10.1111/jcpt.12447. Epub 2016 Sep 19.
3
High prevalence of dyslipidaemia subtypes and their associated personal and clinical attributes in Malaysian adults: the REDISCOVER study.马来西亚成年人血脂异常亚型及其相关个人和临床特征的高患病率:REDISCOVER 研究。
BMC Cardiovasc Disord. 2021 Mar 23;21(1):149. doi: 10.1186/s12872-021-01956-0.
4
Residual cardiovascular risk in individuals on lipid-lowering treatment: quantifying absolute and relative risk in the community.接受降脂治疗个体的残余心血管风险:量化社区中的绝对风险和相对风险。
Open Heart. 2018 Jan 26;5(1):e000722. doi: 10.1136/openhrt-2017-000722. eCollection 2018.
5
Dyslipidaemia in patients with chronic kidney disease - a neglected cardiovascular risk factor.慢性肾脏病患者的血脂异常——被忽视的心血管危险因素。
S Afr Med J. 2023 Nov 6;113(11):35-40. doi: 10.7196/SAMJ.2023.v113i11.1089.
6
Low-Density Lipoprotein Cholesterol Target Attainment in Patients Surviving an Acute Coronary Syndrome in Thailand: Results From the Dyslipidaemia International Study (DYSIS) II.泰国急性冠状动脉综合征存活患者的低密度脂蛋白胆固醇目标达标情况:血脂异常国际研究(DYSIS II)的结果。
Heart Lung Circ. 2020 Mar;29(3):405-413. doi: 10.1016/j.hlc.2019.02.193. Epub 2019 Mar 28.
7
The evaluation of low-density lipoprotein cholesterol goals achieved in patients with established cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering therapy: the South African Not at Goal study (SA-NAG).对接受降脂治疗的已确诊心血管疾病和/或高脂血症患者实现低密度脂蛋白胆固醇目标情况的评估:南非未达目标研究(SA-NAG)
Cardiovasc J Afr. 2008 Mar-Apr;19(2):88-94.
8
Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study.联合治疗与改善 LDL 胆固醇管理相关:来自欧洲观察性 SANTORINI 研究的 1 年随访结果。
Eur J Prev Cardiol. 2024 Nov 11;31(15):1792-1803. doi: 10.1093/eurjpc/zwae199.
9
Factors Associated With Achievement of Blood Pressure, Low-Density Lipoprotein Cholesterol (LDL-C), and Glycemic Targets for Primary Prevention of Cardiovascular Diseases Among High Cardiovascular Risk Malaysians in Primary Care.与马来西亚初级保健中心高心血管风险人群心血管疾病一级预防中血压、低密度脂蛋白胆固醇(LDL-C)和血糖目标达标相关的因素。
J Prim Care Community Health. 2023 Jan-Dec;14:21501319231191017. doi: 10.1177/21501319231191017.
10
The effect of lipid-lowering therapy on lipid-related residual risk factors: a prospective study.降脂治疗对脂质相关残余风险因素的影响:一项前瞻性研究。
Lipids Health Dis. 2024 May 7;23(1):134. doi: 10.1186/s12944-024-02078-0.

引用本文的文献

1
Analyzing lipid profiles and dyslipidemia prevalence in hypertensive patients: a cross-sectional study from primary community health institutions.分析高血压患者的血脂谱和血脂异常患病率:一项来自基层社区卫生机构的横断面研究。
Front Med (Lausanne). 2024 Dec 17;11:1425414. doi: 10.3389/fmed.2024.1425414. eCollection 2024.
2
Factors Associated With Achievement of Blood Pressure, Low-Density Lipoprotein Cholesterol (LDL-C), and Glycemic Targets for Primary Prevention of Cardiovascular Diseases Among High Cardiovascular Risk Malaysians in Primary Care.与马来西亚初级保健中心高心血管风险人群心血管疾病一级预防中血压、低密度脂蛋白胆固醇(LDL-C)和血糖目标达标相关的因素。
J Prim Care Community Health. 2023 Jan-Dec;14:21501319231191017. doi: 10.1177/21501319231191017.

本文引用的文献

1
The alasian alth and Welleing ssessmen (MyHEBAT) Study Protocol: An Initiation of a National Registry for Extended Cardiovascular Risk Evaluation in the Community.亚洲心脏与健康评估(MyHEBAT)研究方案:社区开展的全国心血管扩展风险评估登记研究。
Int J Environ Res Public Health. 2022 Sep 19;19(18):11789. doi: 10.3390/ijerph191811789.
2
Cardiovascular Disease Mortality and Potential Risk Factor in China: A Multi-Dimensional Assessment by a Grey Relational Approach.中国心血管疾病死亡率及潜在危险因素的灰色关联分析
Int J Public Health. 2022 Apr 29;67:1604599. doi: 10.3389/ijph.2022.1604599. eCollection 2022.
3
Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China.中国动脉粥样硬化性心血管疾病风险与降脂治疗需求
Front Cardiovasc Med. 2022 Mar 28;9:839571. doi: 10.3389/fcvm.2022.839571. eCollection 2022.
4
Prevalence and factors associated with lipid-lowering medications use for primary and secondary prevention of cardiovascular diseases among Malaysians: the REDISCOVER study.马来西亚人用于心血管疾病一级和二级预防的降脂药物使用的流行情况及相关因素:REDISCOVER 研究。
BMC Public Health. 2022 Feb 4;22(1):228. doi: 10.1186/s12889-022-12595-1.
5
Addressing dyslipidemic risk beyond LDL-cholesterol.解决 LDL 胆固醇以外的血脂异常风险。
J Clin Invest. 2022 Jan 4;132(1). doi: 10.1172/JCI148559.
6
Association between Dietary Patterns and Low HDL-C among Community-Dwelling Elders in North China.中国北方社区老年人饮食模式与低 HDL-C 的关系。
Nutrients. 2021 Sep 22;13(10):3308. doi: 10.3390/nu13103308.
7
Triglycerides and low HDL cholesterol predict coronary heart disease risk in patients with stable angina.甘油三酯和低 HDL 胆固醇可预测稳定型心绞痛患者的冠心病风险。
Sci Rep. 2021 Oct 20;11(1):20714. doi: 10.1038/s41598-021-00020-3.
8
Systematic Coronary Risk Evaluation (SCORE): JACC Focus Seminar 4/8.系统冠状动脉风险评估(SCORE):JACC 焦点研讨会 4/8。
J Am Coll Cardiol. 2021 Jun 22;77(24):3046-3057. doi: 10.1016/j.jacc.2021.04.052.
9
Global epidemiology of dyslipidaemias.血脂异常的全球流行病学。
Nat Rev Cardiol. 2021 Oct;18(10):689-700. doi: 10.1038/s41569-021-00541-4. Epub 2021 Apr 8.
10
High prevalence of dyslipidaemia subtypes and their associated personal and clinical attributes in Malaysian adults: the REDISCOVER study.马来西亚成年人血脂异常亚型及其相关个人和临床特征的高患病率:REDISCOVER 研究。
BMC Cardiovasc Disord. 2021 Mar 23;21(1):149. doi: 10.1186/s12872-021-01956-0.

马来西亚社区中具有高和极高心血管疾病风险的个体低密度脂蛋白胆固醇(LDL-C)目标的治疗不足与未达目标情况。

Undertreatment and Underachievement of LDL-C Target among Individuals with High and Very High Cardiovascular Risk in the Malaysian Community.

作者信息

Razman Aimi Zafira, Baharudin Noorhida, Mohd Kasim Noor Alicezah, Al-Khateeb Alyaa, Ismail Zaliha, Nawawi Hapizah

机构信息

Institute of Pathology, Laboratory and Forensic Medicine (I-PPerForM), Universiti Teknologi MARA, Sungai Buloh 47000, Selangor, Malaysia.

Department of Primary Care Medicine, Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh 47000, Selangor, Malaysia.

出版信息

Healthcare (Basel). 2022 Dec 5;10(12):2448. doi: 10.3390/healthcare10122448.

DOI:10.3390/healthcare10122448
PMID:36553972
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9777945/
Abstract

Dyslipidaemia is a major cause of morbidity and mortality. The aims of this study are to determine the prevalence of dyslipidaemia subtypes, the proportions of lipid-lowering therapy (LLT) use, and the achievement of low-density lipoprotein cholesterol (LDL-C) treatment targets for high-risk (HR) and very high-risk (VHR) Malaysians. This cross-sectional study involves 5279 participants across 11 states in Malaysia. The data were obtained through a standardised questionnaire, anthropometric measurements, venous glucose and lipid profile. The participants with existing cardiovascular disease (CVD) or diabetes with at least one of the other major risk factors (smoking, hypertension or dyslipidaemia) were grouped into the VHR category. Other participants were risk-categorised using the Framingham General CVD Risk Score (FRS-CVD). The prevalence of elevated LDL-C, LLT use and LDL-C target were set according to respective risk categories. Pearson's chi-squared test was used to test the difference in the proportions. The mean ± standard deviation (SD) age was 41.1 ± 14.8 years, and 62.2% (3283/5279) of the group were females. Within the participant group, 51.5% were found to have elevated total cholesterol, 28.8% had low HDL-C, and 33.8% had high triglyceride. As for elevated LDL-C, 9.8% were in VHR, 8.6% in HR, 5.8% in MR and 34.9% in LR categories. Among the VHR group, 75.8% were not on LLT, and only 15.9% achieved the LDL-C target. As for the HR category, 87.7% were not on LLT, and only 16.1% achieved the LDL-C target. Dyslipidaemia is highly prevalent among Malaysians. The majority of VHR and HR participants were not on LLT and did not achieve LDL-C treatment targets. Proactive programs are warranted to combat dyslipidaemia-associated CVD events in these groups.

摘要

血脂异常是发病和死亡的主要原因。本研究的目的是确定血脂异常亚型的患病率、降脂治疗(LLT)的使用比例,以及马来西亚高危(HR)和极高危(VHR)人群低密度脂蛋白胆固醇(LDL-C)治疗目标的达成情况。这项横断面研究涉及马来西亚11个州的5279名参与者。数据通过标准化问卷、人体测量、静脉血糖和血脂谱获得。患有现有心血管疾病(CVD)或糖尿病且伴有至少一项其他主要危险因素(吸烟、高血压或血脂异常)的参与者被归为VHR类别。其他参与者使用弗雷明汉心血管疾病综合风险评分(FRS-CVD)进行风险分类。根据各自的风险类别设定LDL-C升高、LLT使用情况和LDL-C目标的患病率。采用Pearson卡方检验来检验比例差异。平均年龄±标准差(SD)为41.1±14.8岁,该组中62.2%(3283/5279)为女性。在参与者组中,发现51.5%的人总胆固醇升高,28.8%的人HDL-C低,33.8%的人甘油三酯高。至于LDL-C升高,VHR类别中有9.8%,HR类别中有8.6%,中危(MR)类别中有5.8%,低危(LR)类别中有34.9%。在VHR组中,75.8%未接受LLT治疗,只有15.9%达到了LDL-C目标。至于HR类别,87.7%未接受LLT治疗,只有16.1%达到了LDL-C目标。血脂异常在马来西亚人中非常普遍。大多数VHR和HR参与者未接受LLT治疗,也未达到LDL-C治疗目标。有必要开展积极的项目来对抗这些人群中与血脂异常相关的CVD事件。